Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 5/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | FPR2 | P25090 | 2/20 | 0.38 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | FPR3 | P25089 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1669191 | 0.85 | KDM1A (0.49) | KDM1ANPC1RAB9AMAPTFPR2 | |
| SCHEMBL2745784 | 0.85 | HTR2B (0.49) | NPC1RAB9AMAPTPLA2G4AHTR2B | |
| SCHEMBL15652132 | 0.84 | HTR2B (0.45) | KDM1ANPC1RAB9AMAPTPLA2G4A | |
| SCHEMBL17712058 | 0.82 | PLA2G4A (0.50) | PLA2G4AHTR2BACHEL3MBTL1ALDH1A1 | |
| SCHEMBL16369857 | 0.82 | KDM1A (0.47) | KDM1ANPC1RAB9AMAPTPLA2G4A | |
| SCHEMBL14152154 | 0.80 | HTR2B (0.45) | KDM1ANPC1RAB9AMAPTPLA2G4A | |
| SCHEMBL4688142 | 0.79 | PLA2G4A (0.45) | NPC1RAB9AMAPTPLA2G4AHTR2B | |
| SCHEMBL3001892 | 0.79 | PLA2G4A (0.36) | NPC1RAB9AMAPTPLA2G4AHTR2B | |
| SCHEMBL2990831 | 0.79 | NR1I2 (0.52) | NPC1RAB9AMAPTPLA2G4AHTR2B | |
| SCHEMBL16371343 | 0.77 | MAPT (0.45) | KDM1ANPC1RAB9AMAPTPLA2G4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7427635-B2 | Substituted hydantoins | HOFFMANN-LA ROCHE INC. (US) | 2008-09-23 | — | — | US | claimed |
| EP-1781649-B1 | SUBSTITUTED HYDANTOINS | HOFFMANN LA ROCHE (CH) | 2008-08-13 | — | — | EP | claimed |
| EP-1781649-A2 | SUBSTITUTED HYDANTOINS | F. Hoffmann-Roche AG (CH) | 2007-05-09 | — | — | EP | claimed |
| US-20060041146-A1 | Substituted hydantoins | HOFFMANN-LA ROCHE AG | 2006-02-23 | — | — | US | claimed |
| WO-2006018188-A2 | SUBSTITUTED HYDANTOINS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-02-23 | — | — | WO | claimed |
| US-7427635-B2 | Substituted hydantoins | HOFFMANN-LA ROCHE INC. (US) | 2008-09-23 | — | — | US | disclosed |
| EP-1781649-B1 | SUBSTITUTED HYDANTOINS | HOFFMANN LA ROCHE (CH) | 2008-08-13 | — | — | EP | disclosed |
| EP-1781649-A2 | SUBSTITUTED HYDANTOINS | F. Hoffmann-Roche AG (CH) | 2007-05-09 | — | — | EP | disclosed |
| US-20060041146-A1 | Substituted hydantoins | HOFFMANN-LA ROCHE AG | 2006-02-23 | — | — | US | disclosed |
| WO-2006018188-A2 | SUBSTITUTED HYDANTOINS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-02-23 | — | — | WO | disclosed |
| US-5371097-A | Antiulcer agents | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-12-06 | — | — | US | disclosed |
| US-5364871-A | Antiulcer agents | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-11-15 | — | — | US | disclosed |
| CN-1050191-A | New thiazole derivative, they the preparation method and contain their pharmaceutical composition | FUJISAWA PHARMACEUTICAL CO (JP) | 1991-03-27 | — | — | CN | disclosed |
| EP-0417751-A2 | New thiazole derivatives, processes for the preparation thereof and pharmaceutical compositon comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-03-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060041146-A1 | Substituted hydantoins | HNMT, MAPK6, KYNU | KDM1A 321/4885NPC1 3832/4885RAB9A 764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.